Top Midday Decliners
EyePoint (EYPT) said its phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint. JPMorgan downgraded EyePoint to neutral from overweight.Shares slumped 69% as intraday trading volume catapulted to almost 40.4 million from a daily average of about 1.48 million.Enovix (ENVX) Chief Executive Officer and director Raj Talluri resigned on Aug. 13 to pursue another opportunity, the company said Monday. The company named Chief Financial Officer Ryan Benton interim CEO while conducting an internal and external search for a permanent CEO.Shares plunged 18% as intraday trading volume catapulted to over 24.4 million from a daily average of more than 6.45 million.Corvex (MOVE) reported a wider Q2 loss amid a surge in year-over-year sales late Friday.Shares declined 10%, with intraday trading volume at over 66,000, versus a daily average of about 183,000.Price: $4.53, Change: $-10.23, Percent Change: -69.32%
